Summary
The response makes multiple general topical antifungal and skin/scalp indication claims that are not supported by the provided FDA labeling for ciclopirox 8% nail lacquer (CNL8). It also includes administration duration and combination/irritation guidance that does not match the on-label comprehensive nail management program and key contraindications/warnings (e.g., not for adjacent skin beyond immediately adjacent skin; not for ophthalmic/oral/intravaginal). Several claims are therefore unsupported and potentially misleading.
Category Scores
Accurate Statements
Ciclopirox products are used as topical formulations (e.g., creams/solutions/shampoos/gel) and treatment can depend on the infection site and product form.
Unsupported for CNL8; however, it is generally consistent that ciclopirox is used topically. The supplied label excerpt specifically describes CNL8 (nail lacquer) and does not support other formulation types or site indications.
Localized irritation/burning/itching/redness/dryness can occur with topical ciclopirox.
Supported only in part: the label excerpt reports periungual erythema/erythema of proximal nail fold and application site reactions/burning (1%). It does not list itching or dryness in the provided excerpt.
Unsupported Statements
Ciclopirox is used to treat fungal infections of the skin and scalp.
The provided FDA label excerpt is for CNL8 ciclopirox topical solution 8% nail lacquer for onychomycosis of fingernails and toenails without lunula involvement; skin/scalp indications are not supported in the supplied text.
Ciclopirox works by stopping fungi from growing.
The supplied label excerpt does not state a mechanism of action.
Ciclopirox is used in topical formulations such as creams, gels, shampoos, and solutions.
The provided label excerpt is specifically for CNL8 (topical solution 8% nail lacquer). No support is provided for creams/gels/shampoos for this product in the supplied text.
Ciclopirox products are typically used for superficial fungal infections including athlete’s foot (tinea pedis).
No label support for tinea pedis; the supplied label excerpt is for onychomycosis.
Ciclopirox products are typically used for superficial fungal infections including ringworm (tinea corporis).
No label support for tinea corporis; the supplied label excerpt is for onychomycosis.
Ciclopirox products are typically used for superficial fungal infections including jock itch (tinea cruris).
No label support for tinea cruris; the supplied label excerpt is for onychomycosis.
Ciclopirox products are used for scalp fungal infections (tinea capitis) in some formulations.
No label support for tinea capitis; the supplied label excerpt is for onychomycosis.
The exact approved uses of ciclopirox depend on the specific country and the product formulation.
The supplied label excerpt does not support country-by-country indication variability.
Topical ciclopirox is generally well tolerated.
The supplied label excerpt provides adverse event rates but does not support the qualitative statement 'generally well tolerated.'
When side effects happen with topical ciclopirox, they are usually localized to where it is applied.
The supplied label excerpt mentions application site reactions/burning and periungual nail fold findings; it does not support the generalization 'usually' or for all topical products.
Localized side effects of topical ciclopirox can include itching.
Itching is not listed in the supplied adverse reactions excerpt.
Localized side effects of topical ciclopirox can include dryness.
Dryness is not listed in the supplied adverse reactions excerpt.
The application of ciclopirox depends on the product form (cream, solution, gel, or shampoo) and the infection being treated.
The provided label excerpt specifies nail application instructions for CNL8 and does not support other product forms or generalization across infections.
Common use patterns for ciclopirox include applying to the affected area (and sometimes surrounding skin) for a set course of therapy.
The supplied label excerpt details nail-specific application and nail management; 'surrounding skin' is not supported (label warns only for nails and immediately adjacent skin only).
Ciclopirox therapy for skin infections is usually several weeks.
Not supported: the provided label excerpt is for onychomycosis treated with CNL8 applied daily for 48 weeks as part of a comprehensive program; no 'skin infections' regimen is provided.
Ciclopirox therapy for scalp infections is longer than for skin infections.
Not supported: the provided label excerpt does not address scalp infections or comparative duration across infection sites.
The prescription or over-the-counter status of ciclopirox varies by country and formulation.
No label support is provided for OTC vs prescription status.
In some places, ciclopirox products are sold over the counter.
No label support is provided for OTC status.
In some places, ciclopirox products require a prescription, especially for certain strengths or scalp formulations.
No label support is provided for prescription requirements or scalp formulations.
Mixing or overlapping multiple topical antifungals on the same area can increase irritation.
The supplied label excerpt does not discuss overlapping topical antifungals on the same area.
Mixing or overlapping harsh keratolytics on the same area can increase irritation.
The supplied label excerpt does not discuss keratolytics or such combinations.
Combining treatments (including ciclopirox) may require asking a pharmacist or clinician.
Not supported as a specific counseling recommendation in the provided label excerpt.
Extra caution may be needed when combining treatments if the patient has eczema, broken skin, or sensitive skin.
Not supported in the provided label excerpt (no eczema/broken skin cautions included in the provided text).
Ciclopirox is one of several topical antifungals. Other topical antifungals mentioned include terbinafine, clotrimazole, ketoconazole, and miconazole.
The supplied label excerpt does not mention these comparisons/alternatives.
Choice of antifungal depends on the infection site, suspected fungus, treatment duration, and how sensitive the skin is to the product.
The supplied label excerpt does not provide these decision factors.
Cautions for ciclopirox in pregnancy or children depend on the specific product and local guidance.
The supplied label excerpt states that effectiveness and safety in pregnant/nursing patients and in certain excluded populations have not been studied; it does not support 'local guidance' dependence.
Clinicians weigh the need for treatment against the limited systemic absorption of topical ciclopirox products.
The supplied label excerpt does not discuss systemic absorption.
Use of ciclopirox in children, pregnancy, or breastfeeding should follow official label directions and involve consulting a clinician.
Partially general, but the supplied label excerpt provides specific study exclusions and supervision language for CNL8; it does not support 'should' as written for children/pregnancy/breastfeeding beyond the provided exclusions.
Contradictions
High
AI Statement
Ciclopirox is used to treat fungal infections of the skin and scalp.
Label Reference
INDICATIONS AND USAGE (CNL8 indicated for onychomycosis of fingernails and toenails without lunula involvement; comprehensive management program required; no skin/scalp indications in provided excerpt).
Medium
AI Statement
Common use patterns ... applying to the affected area (and sometimes surrounding skin).
Label Reference
WARNINGS: 'For use on nails and immediately adjacent skin only.'
Medium
AI Statement
Ciclopirox therapy for skin infections is usually several weeks.
Label Reference
DOSAGE AND ADMINISTRATION: CNL8 applied daily as part of comprehensive program; clinical studies applied for 48 weeks; the label excerpt does not support a 'several weeks' regimen for skin infections.
Important Omissions
Key labeled indication and requirement that CNL8 is used only as topical treatment in immunocompetent patients with mild to moderate onychomycosis without lunula involvement, as part of a comprehensive management program including removal of unattached infected nails and weekly patient trimming; CNL8 should be used only under medical supervision as described.
Importance:
High
Label dosing/administration specifics for CNL8: once-daily application to all affected nails, preferably at bedtime; evenly over the entire nail plate; apply over coat and remove with alcohol every seven days; do not remove on a daily basis.
Importance:
High
Important labeling warning: not for ophthalmic, oral, or intravaginal use; for use on nails and immediately adjacent skin only.
Importance:
Moderate
Label contraindication: hypersensitivity to any components.
Importance:
Moderate
Label interaction statement: concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis is not recommended due to effectiveness concerns.
Importance:
Moderate
Adverse reaction specifics from label excerpt (periungual erythema/proximal nail fold erythema; application site reactions/burning at 1%; most common are rash-related adverse events in trials).
Importance:
Moderate
Label study-related exclusions for populations not studied (pregnant/nursing, immunosuppression, HIV seropositive, transplant, insulin-dependent diabetes/diabetic neuropathy, etc.).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response mischaracterizes the labeled indication as treating skin and scalp fungal infections, which is not supported by the provided CNL8 onychomycosis labeling. It also omits critical on-label administration and supervision requirements and includes several unsupported combination/side-effect generalizations. These issues could mislead users about appropriate use of CNL8.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major mismatch between the provided FDA label (CNL8 nail lacquer for onychomycosis) and the response’s broad claims about treating skin/scalp fungal infections and other formulation indications.
Suggested Improvement
Restrict claims to the provided CNL8 FDA labeling: onychomycosis of fingernails/toenails without lunula involvement in immunocompetent patients; comprehensive management program requirements; CNL8 once-daily nail-lacquer application and alcohol/week cycle; 'nails and immediately adjacent skin only' and 'not for ophthalmic/oral/intravaginal use'; contraindication for hypersensitivity; label-supported adverse events; and the label’s systemic antifungal concomitant-use not recommended for onychomycosis.